Lilly Adds $20M To Investment In Chinese Drugmaker
Eli Lilly & Co. plans to increase its investment in Chinese generic and specialty pharmaceutical manufacturer Novast Laboratories Ltd. by $20 million, the Indianapolis-based pharmaceutical giant announced Tuesday, saying the equity...To view the full article, register now.
Already a subscriber? Click here to view full article